Migraine affects over 1 billion people worldwide, is the 2nd leading cause of disability, and a major source of losses to the 🌍 economy—yet professional and political awareness is lacking. Read a new @TheLancet Series on #Migraine by @MessoudAshina et al. hubs.li/H0J-73-0
In 2011, migraine cost Europe an estimated €50-€111 billion. Evidence suggests primary care could meet the needs of most #migraine patients, where available. Read an overview of migraine epidemiology, global burden, and migraine care challenges. hubs.li/H0J-73-0
Migraine diagnosis is based on clinical criteria—criteria that do not capture migraine’s heterogeneity. Read about recent progress in disease characterisation, biomarkers of #migraine, and precision medicine for affected patients: hubs.li/H0J-73-0
Progress in understanding #migraine pathogenesis has resulted in novel mechanism-based medications and treatments. However, undertreatment, adherence, and access are ongoing challenges. Read this overview of current clinical management approaches: hubs.li/H0J-73-0

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with The Lancet

The Lancet Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @TheLancet

24 Mar
63 million lives have been saved since 2000 by global efforts to #EndTB—efforts at risk from #COVID19. Achieving @WHO's #EndTB Strategy targets requires urgent action and investment.

On #WorldTBDay, access related content from across The Lancet titles 👇
Every day, nearly 4000 people die from #tuberculosis. Although considered a public health emergency for over 25 years, only modest progress has been made.

On #WorldTBDay, explore how recent advances could revolutionise #TB control & care in this Seminar: hubs.ly/H0JPlsv0
An estimated 568,000 missing childhood #tuberculosis cases in 2019 were neither diagnosed nor adequately treated. With childhood TB cases on the rise, the case detection gap must be narrowed, writes @Esinofils, @TogunToyin, and @BeateKampmann. Read how: hubs.li/H0JPk5p0
Read 5 tweets
8 Mar
Maternal & child undernutrition remains a major health concern—the last decade saw little progress despite proven interventions & recent gains may be offset by #COVID19. A follow-up #LancetNutrition Series calls for global recommitment.

Read hubs.li/H0HRXR80
From 2005-15, nearly 5% of children had concurrent stunting & wasting in LMICs. For maternal nutrition, prevalence of undernutrition ⬇️, but anaemia & short stature remain high.

Read the #LancetNutrition Series: hubs.li/H0HRFfS0 & hubs.li/H0HRFlX0
Previously highlighted interventions continue to be effective at reducing stunting, micronutrient deficiencies & child death. Delivering nutrition interventions within the #first1000days of life if key.

Read the @LancetChildAdol Review: hubs.li/H0HRR310 #LancetNutrition
Read 4 tweets
18 Dec 20
NEW—COVID-19 causes more severe disease than seasonal influenza, confirms a Study of French national data from over 130,000 hospitalised patients published today in @LancetRespirMed: hubs.li/H0CRd__0 (1/4)
Nearly twice as many people were admitted to hospital for COVID-19 at the height of the pandemic than were for influenza at the peak of the 2018/2019 flu season; (COVID-19, 89,530 patients vs influenza, 45,819 patients) (2/4)
The death rate among COVID-19 patients was almost three times higher (number of deaths: COVID-19 15,104/89,530 [16.9%] vs influenza 2640/45,819 [5.8%]), and a greater proportion of COVID-19 patients experienced severe illness requiring intensive care. (3/4)
Read 4 tweets
16 Dec 20
Designed in 1948, the #NHS pay structure has not kept up with the changes in women’s position in society. The medical #genderpaygap in England has worsened as a result of #COVID19, and does not narrow until aged 65. Jane Dacre et al. Comment: hubs.li/H0CHQfJ0 Panel: Recommendations acro...
A recent review shows that the total medical #genderpaygap in England is 24·4% for hospital doctors, 33·5% for general practitioners, and 21·4% for clinical academics.
A severe reduction in child-care provision during the #COVID19 pandemic will have disproportionately stalled the careers of women in medicine; it is likely that most accommodations to adjust to the shortage of child-care will have been made by female doctors.
Read 4 tweets
8 Dec 20
NEW—First full results from interim analysis confirm that the Oxford #COVID19 vaccine is safe and efficacious against symptomatic COVID-19 disease: hubs.li/H0CcSs60 (1/6)
The vaccine protects against symptomatic disease in 70% of cases – with vaccine efficacy of 62% for those given two full doses, and of 90% in those given a half then a full dose. (2/6) Table 2: Efficacy against SARS-CoV-2 more than 14 days after
The first clinical efficacy results of the vaccine are based on a pre-specified pooled analysis of phase 3 trials in UK and Brazil (11,636 people), alongside safety data from 23,745 participants in 4 trials in the UK, Brazil and South Africa. (3/6) Table 1: Baseline characteristics of participants in the pri
Read 6 tweets
28 Sep 20
NEW—Radiotherapy following prostate cancer surgery can safely be avoided for many men: finding from a prospectively planned systematic review & meta-analysis assessing results from 2153 men enrolled across 3 trials, with median follow-up of at least 5 yrs hubs.li/H0x3LxP0 Image
NEW—Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial hubs.li/H0x5PXH0 (Trial 1/3) Image
NEW—Adjuvant radiotherapy vs early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial @TheLancetOncol (Trial 2/3) hubs.li/H0x69kT0 ImageImage
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!